A Phase II Study of Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707 (Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401

Wieduwilt Matthew J.; Jonas Brian A.; Schiller Gary J.; Liu Lin; Mulroney Carolyn; Mannis Gabriel N.; Tzachanis Dimitrios; Castro Januario E.; Ball Edward D.; Curtin Peter T.; Andreadis Charalambos; Logan Aaron C.; Reiner Jesika; Damon Lloyd E.

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >A Phase II Study of Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707 (Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401

【24h】

A Phase II Study of Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707 (Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401

机译：将Pegymated天酰胺酶，环磷酰胺，rituximab和Dasatinib的II类研究加入到UCSF 8707（Linker 4-药物）方案中，具有脂质体溶血素CNS预防，用于具有新诊断的急性淋巴细胞白血病（ALL）或淋巴细胞淋巴瘤（LBL）：大学加利福尼亚血液学恶性肿瘤联盟研究（UCHMC）1401

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共4页
作者
Wieduwilt Matthew J.; Jonas Brian A.; Schiller Gary J.; Liu Lin; Mulroney Carolyn; Mannis Gabriel N.; Tzachanis Dimitrios; Castro Januario E.; Ball Edward D.; Curtin Peter T.; Andreadis Charalambos; Logan Aaron C.; Reiner Jesika; Damon Lloyd E.;
展开▼
作者单位

Univ Calif San Diego Moores Canc Ctr La Jolla CA 92093 USA;

Univ Calif Davis Ctr Comprehens Canc Sacramento CA 95817 USA;

Univ Calif Los Angeles David Geffen Sch Med Los Angeles CA 90095 USA;

Univ Calif San Diego La Jolla CA 92093 USA;

Univ Calif San Diego Moores Canc Ctr La Jolla CA 92093 USA;

Univ Calif San Francisco Div Hematol &

Blood &

Marrow Transplantat San Francisco CA 94143 USA;

Univ Calif San Diego La Jolla CA 92093 USA;

Mayo Clin Scottsdale AZ USA;

Univ Calif San Diego Dept Med BMT Div La Jolla CA 92093 USA;

Univ Calif San Diego Moores Canc Ctr La Jolla CA 92093 USA;

Univ Calif San Francisco Helen Diller Family Comprehens Canc Ctr San Francisco CA 94143 USA;

Univ Calif San Francisco Div Hematol &

Oncol San Francisco CA 94143 USA;

Univ Calif San Diego Moores Canc Ctr La Jolla CA 92093 USA;

Univ Calif San Francisco Div Hematol &

Blood &

Marrow Transplantat San Francisco CA 94143 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献

1. A Phase II Study of Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707 (Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401 [J] . Wieduwilt Matthew J., Jonas Brian A., Schiller Gary J., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：将Pegymated天酰胺酶，环磷酰胺，rituximab和Dasatinib的II类研究加入到UCSF 8707（Linker 4-药物）方案中，具有脂质体溶血素CNS预防，用于具有新诊断的急性淋巴细胞白血病（ALL）或淋巴细胞淋巴瘤（LBL）：大学加利福尼亚血液学恶性肿瘤联盟研究（UCHMC）1401
2. Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Is Active and Well-Tolerated in Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL): Initial Results of a Phase II Trial [J] . Cassaday Ryan D., Soma Lorinda A., Sala-Torra Olga, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：剂量调节的依托磷脂，泼尼松，长春酮，环磷酰胺和多柔比星（DA-EPOCH）在具有新诊断的急性淋巴细胞白血病/淋巴瘤（ALL）的成人中是活性和良好的耐受性：II期试验的初始结果
3. Randomized Study of Pegasparagase (SS-PEG) and Calaspargase Pegol (SC-PEG) in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Results of DFCI ALL Consortium Protocol 11-001 [J] . Silverman Lewis B., Blonquist Traci M., Hunt Sarah K., Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：新诊断为急性淋巴细胞白血病或淋巴母细胞性淋巴瘤的儿科患者中天加门冬酰胺（SS-PEG）和Calaspargase聚乙二醇（SC-PEG）的随机研究：DFCI ALL联合实验方案11-001的结果
4. Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study [O] . Wen-jian Liu, Hua Wang, Wei-da Wang, -1

机译：与大肠杆菌-天冬酰胺酶相比PEG-天冬酰胺酶在新诊断的具有标准风险的急性淋巴细胞白血病患者中的应用：回顾性单中心研究
5. Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study [O] . Wen-jian Liu, Hua Wang, Wei-da Wang, 2016

机译：使用标准风险急性淋巴细胞白血病的新诊断的成人使用PEG-天冬酰胺酶与大肠杆菌芦笋酶：回顾性单中心研究

著录项

引文网络

相似文献

相关主题

期刊订阅